Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study

Open access
Fadini, Gian Paolo, Feher, Michael, Hansen, Troels Krarup, de Valk, Harold W, Koefoed, Mette Marie, Wolden, Michael, Zimmermann, Esther, Jendle, Johan · 2019 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Observational studies of insulin degludec (degludec) with hypoglycemia events prospectively recorded are lacking. Objective: To evaluate the safety and effectiveness of degludec in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) switching from other basal insulins in routine care. Design: Results From Real-World Clinical Treatment With Tresiba® was a multinational, multicenter, prospective, observational, single-arm study comprising a 4-week baseline period (preswitch basal insulin) and 12-month follow-up (degludec). Setting: Routine clinical practice. Patients or Other Participants: Insulin-treated patients (≥18 years) with T1D (n = 556) or T2D (n = 611) with treatment plans to initiate degludec. Interventions: Switching to degludec from other basal insulins. Main Outcome Measure: Change from baseline in number of overall hypoglycemic events recorded in patient diaries. Results: In T1D, the 12-month follow-up/baseline rate ratios (95% CI) of overall [0.80 (0.74 to 0.88)], nonsevere [0.83 (0.76 to 0.91)], severe [0.28 (0.14 to 0.56)], and nocturnal [0.61 (0.50 to 0.73)] hypoglycemia suggested significantly lower hypoglycemia rates with degludec (all Ps < 0.001). At 12 months, HbA1c, fasting plasma glucose (FPG), and basal insulin dosage decreased significantly. Body weight increased, and treatment satisfaction improved significantly. In T2D, the hypoglycemia rate ratios were overall [0.46 (0.38 to 0.56)], nonsevere [0.53 (0.44 to 0.64)], and nocturnal [0.35 (0.20 to 0.62)] (all Ps < 0.001; too few events for analysis of severe hypoglycemia). At 12 months, HbA1c and FPG decreased significantly. Body weight and insulin dosages remained unchanged, and treatment satisfaction was significantly improved. Conclusions: In a routine clinical care setting, switching to degludec from other basal insulins was associated with significantly lower rates of hypoglycemia, improved glycemic control, and treatment satisfaction in patients with T1D or T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2019-01021

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic of trial design. (A) Patient disposition and (B) trial design. Gray arrows indicate 4-wk periods when hypoglycemic episodes will be recorded prospectively in patient diaries. Visits are defined as contact with the treating physician. OD, once daily.
Figure 1. Schematic of trial design. (A) Patient disposition and (B) trial design. Gray arrows indicate 4-wk periods when hypoglycemic episodes will be recorded prospectively in patient diaries. Visits are defined as contact with the treating physician. OD, once daily.CC BY · PubMed Central
Figure 2. Patient disposition.
Figure 2. Patient disposition.CC BY · PubMed Central
Figure 3. Hypoglycemia in patients with T1D or T2D during the 12-mo follow-up period vs the 4-wk baseline period. Hypoglycemia was analyzed via a negative binomial regression model controlled for period (pre/post), age, sex, HbA1c, diabetes duration, BMI, and country. For T2D, additional covariates included prandial insulin (yes or no) and sulfonylurea + glinides (yes or no). Total follow-up time (patient-years) for T1D was 38.5 and 104.5 for the 4-wk baseline period and the 12-mo follow-up period, respectively. Total follow-up time (patient-years) for T2D was 40.8 and 118.8 for the 4-wk baseline period and the 12-mo follow-up period, respectively. N/A, severe hypoglycemia could not be analyzed because of the low number of events. E, number of events; N, number of patients; R, number of events per patient-year of exposure.
Figure 3. Hypoglycemia in patients with T1D or T2D during the 12-mo follow-up period vs the 4-wk baseline period. Hypoglycemia was analyzed via a negative binomial regression model controlled for period (pre/post), age, sex, HbA1c, diabetes duration, BMI, and country. For T2D, additional covariates included prandial insulin (yes or no) and sulfonylurea + glinides (yes or no). Total follow-up time (patient-years) for T1D was 38.5 and 104.5 for the 4-wk baseline period and the 12-mo follow-up period, respectively. Total follow-up time (patient-years) for T2D was 40.8 and 118.8 for the 4-wk baseline period and the 12-mo follow-up period, respectively. N/A, severe hypoglycemia could not be analyzed because of the low number of events. E, number of events; N, number of patients; R, number of events per patient-year of exposure.CC BY · PubMed Central
Figure 4. Sensitivity analyses in overall hypoglycemia in patients with T1D or T2D during the 12-mo follow-up period vs the 4-wk baseline period. Sensitivity analysis 1 is based on the 26- to 30-d diary period, where the dates of hypoglycemic events recorded on the hypoglycemia page fell within the diary period. Sensitivity analysis 2 is based on all diaries, where the dates of hypoglycemic events recorded on the hypoglycemia page matched the events in the diary exactly. Sensitivity analysis 3 is based on all diaries, where the dates of hypoglycemic events recorded on the hypoglycemia page fell within the diary period. Sensitivity analysis 4 is based on the 26- to 30-d diary period, where the dates of hypoglycemic events recorded on the hypoglycemia page matched the events in the diary exactly for patients with a minimum of 23 diary days for each diary period, who completed 12 mo observation. E, number of events; N, number of patients; R, estimated number of events per patient-year.
Figure 4. Sensitivity analyses in overall hypoglycemia in patients with T1D or T2D during the 12-mo follow-up period vs the 4-wk baseline period. Sensitivity analysis 1 is based on the 26- to 30-d diary period, where the dates of hypoglycemic events recorded on the hypoglycemia page fell within the diary period. Sensitivity analysis 2 is based on all diaries, where the dates of hypoglycemic events recorded on the hypoglycemia page matched the events in the diary exactly. Sensitivity analysis 3 is based on all diaries, where the dates of hypoglycemic events recorded on the hypoglycemia page fell within the diary period. Sensitivity analysis 4 is based on the 26- to 30-d diary period, where the dates of hypoglycemic events recorded on the hypoglycemia page matched the events in the diary exactly for patients with a minimum of 23 diary days for each diary period, who completed 12 mo observation. E, number of events; N, number of patients; R, estimated number of events per patient-year.CC BY · PubMed Central
Figure 5. Observed mean (SD) (A) HbA1c and (B) FPG for patients with T1D or T2D after switch to degludec from other basal insulins.
Figure 5. Observed mean (SD) (A) HbA1c and (B) FPG for patients with T1D or T2D after switch to degludec from other basal insulins.CC BY · PubMed Central
Figure 6. Observed mean (SD) (A) basal, (B) bolus, and (C) total insulin dose over time in patients with T1D or T2D after switch to degludec from other basal insulins.
Figure 6. Observed mean (SD) (A) basal, (B) bolus, and (C) total insulin dose over time in patients with T1D or T2D after switch to degludec from other basal insulins.CC BY · PubMed Central
Figure 7. Observed mean (SD) body weight over time in patients with T1D or T2D after switch to degludec from other basal insulins.
Figure 7. Observed mean (SD) body weight over time in patients with T1D or T2D after switch to degludec from other basal insulins.CC BY · PubMed Central
Figure 8. Mean treatment satisfaction in DTSQ-s in patients with (A) T1D or (B) T2D. Asterisks indicate significant differences. Data are changes between the 4-wk baseline period and the 12-mo follow-up period (95% CI). DTSQ-s scores range from 6 (very satisfied) to 0 (very dissatisfied). For the final question regarding perceived frequency of hypoglycemia, this question is treated separately from the other questions, and a low score represents good perceived blood glucose control.
Figure 8. Mean treatment satisfaction in DTSQ-s in patients with (A) T1D or (B) T2D. Asterisks indicate significant differences. Data are changes between the 4-wk baseline period and the 12-mo follow-up period (95% CI). DTSQ-s scores range from 6 (very satisfied) to 0 (very dissatisfied). For the final question regarding perceived frequency of hypoglycemia, this question is treated separately from the other questions, and a low score represents good perceived blood glucose control.CC BY · PubMed Central
Figure 9. PROs in SF-36® v2 for patients with (A) T1D or (B) T2D. Asterisks indicate significant differences. Data are changes between the 4-wk baseline period and the 12-mo follow-up period (95% CI).
Figure 9. PROs in SF-36® v2 for patients with (A) T1D or (B) T2D. Asterisks indicate significant differences. Data are changes between the 4-wk baseline period and the 12-mo follow-up period (95% CI).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 27

Metadata

Authors
Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J.
Affiliations
  • University of Padua (IT)
  • University of Surrey (GB)
  • Aarhus University Hospital (DK)
  • Department of Internal Medicine, University Medical Center Utrecht, CX Utrecht, Netherlands
  • Novo Nordisk (Denmark) (DK)
  • Örebro University (SE)
Corresponding author
Fadini, Gian Paolo
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-08-09
Volume
104
Issue
12
Pages
5977-5990
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2968305708
Cited by
27
References
34
Citations by year
2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 6
FWCI
3.04
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
insulin degludec, basal insulin switching, hypoglycemia, type 1 diabetes, type 2 diabetes, nocturnal hypoglycemia, HbA1c, fasting blood glucose, treatment satisfaction, body weight, insulin dose, real-world clinical practice, patient diary, insulin analogues, glycemic control, safety and effectiveness
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Europe, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Insulin, Long-Acting, Drug Substitution, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. https://app.cochat.ai/papers/10.1210/jc.2019-01021
The paper
Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J. (2019). Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2019-01021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.